← Leaderboards
Jason Ken Hou
Baylor College Of Medicine
$766,020
Attributed
$766,020
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $153.4K · FY2015–25$200K$150K$100K$50K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
AHRQ$766,020 · 1
VA$0 · 2
By mechanism
K08$766,020 · 1
I01$0 · 2
Top collaborators
- Akbar K Waljee7 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Mark E. Kunik$3,352,777
- C P Steuber$1,047,551
- Barbara Wells Trautner$5,824,768
Others in their field
Top investigators on “Veterans”
- David R. Weir · University Of Michigan At Ann Arbor$296,295,927
- Charles A Coltman · Southwest Oncology Group$122,561,996
- Jennifer A Pietenpol · Vanderbilt University$60,636,894
- Fred M Gordin · Social And Scientific Systems, Inc.$59,139,975
- Adrian Hernandez · Duke University$50,769,596
- Michael W. Konstan · Case Western Reserve University$48,783,827
Research focus
VeteransTnf GeneUlcerative ColitisMethodologyProviderStructureOperative Surgical ProceduresImmuneLearningMediatingPharmaceutical PreparationsPoliciesS DiseaseBiologicalAdverse EventInflammatory Bowel DiseasesHealth SystemHospitalizationCaringInnovationChronicCostCrohn&AposHealthcare
Grant awards (12)
A learning health system approach to using Artificial Intelligence Enabled Decision Support (AEDS) for medication optimization in Veteran Care: An Immunosuppressants use case$0
I01 · FY2025 · VA
Effectivenes, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease$0
I01 · FY2024 · VA · contact PI
A learning health system approach to using Artificial Intelligence Enabled Decision Support (AEDS) for medication optimization in Veteran Care: An Immunosuppressants use case$0
I01 · FY2024 · VA
Effectivenes, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease$0
I01 · FY2023 · VA · contact PI
Effectivenes, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease$0
I01 · FY2022 · VA · contact PI
Effectivenes, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease$0
I01 · FY2021 · VA · contact PI
Effectivenes, Safety, and Patient Preferences of Infliximab Biosimilar Medications for Inflammatory Bowel Disease$0
I01 · FY2020 · VA · contact PI
Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD$152,580
K08 · FY2019 · HS · contact PI
Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD$153,360
K08 · FY2018 · HS · contact PI
Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD$153,360
K08 · FY2017 · HS · contact PI
Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD$153,360
K08 · FY2016 · HS · contact PI
Patient-Centered Comparative Effectiveness of Colorectal Cancer Surveillance in IBD$153,360
K08 · FY2015 · HS · contact PI